Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13

...ent, Commercial Operations, Santarus, Inc. mmx (R) Technology - The Benefits of Targeted Deliv...rohn's and Colitis Organization Budesonide mmx (R) - Clinical Development Program in Ulcerative ...g Center for Travelers' Health Rifamycin SV mmx (R) - Clinical Development Program in Traveler'...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...y ulcerative colitis treatment that utilizes MMX(R) Technology. Lialda with mmx Technology combines a pH dependent gastro-resistant coating, which delays t...ialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. For further information please contact: Investor Relatio...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...y ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays t...ialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. Important Safety Information for LIALDA LIALDA tablets are ...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...tment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistan...y. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. Important Safety Information for LIA...ani and Shire Pharmaceuticals. Cosmo's proprietary mmx technology is at the core of the company's product...

LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

...on, with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. LIALDA is the only ulcerative colitis treatment that utilizes mmx Technology. In two pivotal phase III clinical studies, LIALDA was shown to be superior to placebo in inducing remission and treating the symptoms ...

MMX in Medical Technology

Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

-- Primary endpoint achieved -- LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA (SWX:COPN) announced today positive preliminary results from its phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) in infectious diarrhoea. CB-01-11 is a broad spectrum, semi-synthetic antibiotic that...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...y ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays t...ialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. SHIRE PLC Shire's strategic goal is to become the leading s...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...tment that utilizes MMX(R) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistan...y. Cosmo Pharmaceuticals SpA, Milan, developed the mmx Technology. For more information about LIALDA and...ani and Shire Pharmaceuticals. Cosmo's proprietary mmx Technology is at the core of the company's product...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

...new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

...new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with mmx Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ...

MMX in Biological Technology

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

...ally the patient population who may benefit most." Once-daily LIALDA with mmx technology contains the highest mesalamine dose per tablet (1.2 g), so pati...ialisation rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the mmx technology. For more information about LIALDA and for Full Prescribing In...